Invivyd, Inc. has started the FLINTLOCK Phase 2 clinical trial to test the safety and effectiveness of its monoclonal antibody VYD2311 for treating Long COVID and Post-Vaccination Syndrome (PVS). The trial will enroll adults aged 18-65 with persistent symptoms lasting over six months after COVID-19 infection or vaccination. VYD2311 has shown strong antiviral activity against all tested SARS-CoV-2 variants, and the study aims to evaluate its potential as a therapeutic option over a 90-day period. Initial results are expected by mid-2027, addressing a significant unmet need for effective Long COVID treatments.
Invivyd's FLINTLOCK Phase 2 study for Long COVID and Post-Vaccination Syndrome treatment is underway. For readers following the Health sector, here is Pluang's market snapshot as of Oct 14, 2026 17:11 WIB: out of 150 priced Health-sector US stocks, 98 rose and 44 fell. Notable moves include GH (Guardant Health Inc.) at USD 158.20 with a 1-day change of -2.40% and 100% buy order activity, ARWR (Arrowhead Pharmaceuticals Inc.) at USD 59.44 up 2.25%, and DNA (Ginkgo Bioworks Holdings Inc.) at USD 12.02 up 2.21% with a balanced buy/sell order activity.
Genesis Global won the Best AI Solution for Software Development award at the 2026 AI in Capital Markets Awards for its product Genesis Create. This software combines AI with reusable components and financial expertise to help firms develop productio...
nuVizz has been recognized as an Accelerator in the 2026 Nucleus Research Transportation Management Value Matrix for its specialized last-mile delivery technology. The platform excels in coordinating complex delivery networks involving private fleets...
ASML Holding posted a strong Q3 2026 earnings per share of $14.65, beating estimates of $12.17, driven by a 55% year-over-year sales growth and a 57.5% gross margin. Although revenue was slightly below expectations at $13.05 billion, the company bene...
Charles Schwab is set to report its Q3 2026 earnings with an estimated EPS of $1.66 and revenue around $7.18-$7.19 billion, reflecting significant growth driven by an 18.2% increase in trading revenue, net interest income, and asset management fees. ...
Transmission System Operators (TSOs) are increasingly investing in software like Energy Management Systems and grid planning tools to modernize aging infrastructure, enhance cybersecurity, and expand grid capacity. Cybersecurity remains their top con...
